Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.
Journal
Current hematologic malignancy reports
Journal Volume
20
Journal Issue
1
Start Page
Article number 9
ISSN
1558-822X
Date Issued
2025-07-12
Author(s)
Bose, Prithviraj
Xiao, Zhijian
Hasselbalch, Hans C
Prchal, Josef T
Duan, Minghui
Yacoub, Abdulraheem
Rampal, Raajit
Kiladjian, Jean-Jacques
Hobbs, Gabriela S
Tashi, Tsewang
Shimoda, Kazuya
Kirito, Keita
Gill, Harinder
Lee, Sung-Eun
Huang, Jian
Li, Bing
Qin, Albert
Yu, Lennex Hsueh-Lin
Mascarenhas, John O
Mesa, Ruben A
Abstract
Purpose of Review: This report summarizes key insights from the 8th Annual International Symposium on Myeloproliferative Neoplasms (MPN Asia 2025). The symposium brought together global experts to discuss advancements in MPN biology, diagnostics, and therapeutics, with a focus on emerging molecular understanding, novel treatment strategies and real-world data. Recent Findings: Molecular profiling has become essential in MPN risk stratification and therapeutic decision-making. High-risk mutations (e.g., ASXL1, TP53) and inflammatory pathways (e.g., IL-17, NF-κB) were shown to correlate with disease progression and transformation. Interferon-based therapy is increasingly used in younger, low-risk, or treatment-naïve patients, and is also being investigated in myelofibrosis and essential thrombocythemia. Ropeginterferon alfa-2b, a novel interferon-based therapy, demonstrated durable clinical efficacy in polycythemia vera. Its high initial-dose and accelerated titration (HIDAT) regimen led to fast achievement of complete hematologic response, rapid reductions in JAK2V617F allele burden, and high complete molecular response rate. Combination regimens involving ruxolitinib and agents such as pelabresib, selinexor, and interferon showed potential for enhanced efficacy. Population-based studies from Asia contributed regional epidemiological and treatment data, reinforcing the role of real-world evidence. Modern prognostic models such as MIPSS70+ v2.0 and GIPSS were discussed for more precise risk prediction. Preliminary findings also suggest ropeginterferon alfa-2b may be a safe option during pregnancy. Summary: MPN Asia 2025 highlighted the growing role of molecular diagnostics and targeted therapeutics in the management of MPNs. Ropeginterferon alfa-2b has emerged as a therapeutic potential across the MPN spectrum. Its early use and personalized strategies are increasingly recognized. Real-world data and regional insights are shaping a more nuanced, globally informed approach to MPN care.
Type
review article